<DOC>
	<DOCNO>NCT02003339</DOCNO>
	<brief_summary>For patient suffer hepatocellular carcinoma treat radioembolization , purpose study analyse parameter functional MRIs modify early detect parameter vary significantly treatment .</brief_summary>
	<brief_title>Interest Functional MRI ( Magnetic Resonance Imagery ) ( Patients Suffering From Hepatocellular Carcinoma Treated With Yttrium</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Early , intermediate , advanced , non metastatic Hepatocellular Carcinoma . Indication radioembolization validate pluridisciplinary committee meeting . Isolated target initial imagery ( invasive hepatocellular carcinoma exclude ) WHO ( World Health organization ) Performance status : 0 , 1 2 If cirrhosis , Child A score total bilirubin le 30 micromoles per liter Creatinine clearance equal 30 mL/min Patient inform consent signature obtain Invasive hepatocellular carcinoma without isolated tumor Disease need 2 injection Therasphere Thrombosis extend porta ( thrombosis one leave right branch authorize ) , extra hepatic metastasis Previous treatment chemoembolization , radiofrequency le 3 month radioembolization No antiangiogenic concomitant treatment , 15 day 15 day radioembolization , include Sorafenib Associated disease could prevent patient receive treatment RMI contreindication ( particle metal prosthesis , pacemaker , claustrophobia ) contrast product contreindication ( allergy ) Patient already participate therapeutic trial experimental drug Pregnant childbearing potential woman breastfeed woman minor , person deprive liberty protect adult ( maintenance justice , guardianship supervision ) Unable comply trial medical followup geographical , social psychological reason Unable sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>